Related Experiment Video
Updated: Jun 10, 2025
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.3K
Biologics in Food Allergies: Emerging Therapies
Michele Beaudoin1, Chloe Citron1, Kanwaljit K Brar2
1Department of Pediatrics, NYU Grossman School of Medicine, Hassenfeld Children's Hospital, 430 East 34th Street, New York, NY 10016, USA.
Immunology and Allergy Clinics of North America
|October 10, 2024
Summary
New treatments like Omalizumab offer hope for managing IgE-mediated food allergies, reducing risks and improving quality of life for patients and families. These advancements move beyond traditional allergen avoidance for better food allergy management.
Area of Science:
- Immunology
- Allergy and Immunology
- Pharmacology
Background:
- IgE-mediated food allergies cause significant patient distress and risk of severe reactions.
- Current management relies on allergen avoidance and emergency treatment.
- Recent advancements offer new therapeutic avenues.
Purpose of the Study:
- To review the emerging therapeutic landscape for IgE-mediated food allergies.
- To highlight the role of Omalizumab and other novel biologics.
- To discuss potential combination therapies.
Main Methods:
- Review of recent clinical trials and therapeutic approvals.
- Analysis of Omalizumab's efficacy in preventing allergic reactions.
- Exploration of biologics and small molecule inhibitors in food allergy.
Main Results:
- Omalizumab approved for preventing serious allergic reactions in allergic individuals over one year old.
- Omalizumab shows potential in conjunction with oral immunotherapy.
- Other biologics and small molecules demonstrate promise in food allergy treatment.
Conclusions:
- Omalizumab represents a significant advancement in managing IgE-mediated food allergies.
- Novel therapeutic classes offer new hope for prevention and treatment.
- Future research directions include combination therapies and broader biologic applications.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:30Hypersensitivities
536
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
536
01:29Microorganisms in Medicine and Therapeutics
2
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
2
01:27Allergic Drug Reactions
817
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
817
00:42Cross-reactivity
31.0K
Overview
31.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117